Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LUX-Lung: determining the best EGFR inhibitor in NSCLC?

The Lancet. Oncology - 1 Feb 2015

Rossi Antonio, Di Maio Massimo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Afatinib
Share to Antineoplastic Combined Chemotherapy Protocols
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Quinazolines

Source

Identifiers

PMID: 25589190
DOI: 10.1016/S1470-2045(14)71196-9

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LUX-Lung: determining the best EGFR inhibitor in NSCLC?PMID 25589190Read ↗

Optimising therapy for EGFR-addicted NSCLC: just the start.Semantic proximity Read ↗

Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?Semantic proximity Read ↗

[Application strategies of the third-generation EGFR-TKI in the context of precision medicine].Semantic proximity Read ↗

The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.Semantic proximity Read ↗

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?Semantic proximity Read ↗

[I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].Semantic proximity Read ↗

EGFR antagonists in cancer treatment.Semantic proximity Read ↗

Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?Semantic proximity Read ↗

Combination regimens in EGFR-mutated lung cancer: can we get ORIENT-ed?Semantic proximity Read ↗

LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohortsSemantic proximity Read ↗

Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?Semantic proximity Read ↗

Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.